VIRP logo

Virbac SA Stock Price

ENXTPA:VIRP Community·€2.7b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author
Create a narrative

VIRP Share Price Performance

€318.00
-56.50 (-15.09%)
20.0% undervalued intrinsic discount
€397.61
Fair Value
€318.00
-56.50 (-15.09%)
19.5% undervalued intrinsic discount
€395.17
Fair Value
Price €318.00
AnalystConsensusTarget €395.17

VIRP Community Narratives

AnalystConsensusTarget·Updated
Fair Value €397.61 20.0% undervalued intrinsic discount

Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative

Recent VIRP News & Updates

Is There An Opportunity With Virbac SA's (EPA:VIRP) 43% Undervaluation?

Oct 05
Is There An Opportunity With Virbac SA's (EPA:VIRP) 43% Undervaluation?

Analysts Have Made A Financial Statement On Virbac SA's (EPA:VIRP) First-Quarter Report

Sep 17
Analysts Have Made A Financial Statement On Virbac SA's (EPA:VIRP) First-Quarter Report

There's Reason For Concern Over Virbac SA's (EPA:VIRP) Price

Aug 30
There's Reason For Concern Over Virbac SA's (EPA:VIRP) Price

Is There An Opportunity With Virbac SA's (EPA:VIRP) 46% Undervaluation?

Jun 23
Is There An Opportunity With Virbac SA's (EPA:VIRP) 46% Undervaluation?

Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected

May 18
Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected

Virbac (EPA:VIRP) Seems To Use Debt Quite Sensibly

Apr 30
Virbac (EPA:VIRP) Seems To Use Debt Quite Sensibly
User avatar

Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals

Strategic R&D investments and facility expansions aim to drive innovation, operational efficiency, and future revenue growth, potentially enhancing profitability.

Virbac SA Key Details

€1.4b

Revenue

€476.9m

Cost of Revenue

€955.9m

Gross Profit

€822.8m

Other Expenses

€133.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Jan 15, 2026
Earnings per share (EPS)
15.88
Gross Margin
66.72%
Net Profit Margin
9.29%
Debt/Equity Ratio
27.2%

Virbac SA Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Flawless balance sheet and good value.

0 Risks
3 Rewards
View Full Analysis

About VIRP

Founded
1968
Employees
6365
CEO
Paul Martingell
WebsiteView website
corporate.virbac.com

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. It serves veterinarians, farmers, and pet owners. The company was founded in 1968 and is headquartered in Carros, France.

Market Insight

Header cover image

✨Rare Earths: Tiny Market, Outsized Influence

Richard Bowman avatarRichard Bowman
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Last Week
⚡ Utilities: Defensive Dividends Meet the AI Power Surge

⚡ Utilities: Defensive Dividends Meet the AI Power Surge

French Market Performance

  • 7 Days: 2.5%
  • 3 Months: 3.4%
  • 1 Year: 4.9%
  • Year to Date: 7.5%
The market has climbed 2.5% over the last week, with theConsumer Discretionary and Materials sectors leading the way. In contrast, the Energy sector is lagging, dropping 5.0%. In the last year, the market has climbed 4.9%. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›